Brand & Product Security

Articles

Getting a handle on level of compliance-readiness for the Drug Supply Chain Security Act deadline—now just weeks away.

A Sense of Urgency

Webinar Date/Time: Tue, Oct 22, 2024 11:00 AM EDT



DSCSA Beyond the November Deadline: Operationalizing Compliance in the Warehouse

As the dust settles on the first round of Medicare negotiations, not everything is what it seems.


Reflections on IRA Drug Pricing Negotiations

The session details how these teachings span the entire pharma supply chain.

LogiPharma USA 2024: Lessons Learned from Risk Mitigation 

A panel offers its perspective on bolstering the temperature monitoring and data sharing process. 

LogiPharma USA 2024: Enhancing Cold Chain Insights

With the Nov. 27 deadline fast approaching, is the pharma supply chain ready for full data exchange?

LogiPharma USA 2024: Working Toward DSCSA Compliance

Bimzelx is the first approved medication for active psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis that selectively inhibits IL-17A and IL-17F, both of which are key cytokines that drive inflammatory processes.

FDA Approves Bimzelx for Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis 

Accord BioPharma's 420 mg strength Hercessi (trastuzumab-strf), a biosimilar to Herceptin, gains FDA approval to treat HER2-overexpressing breast cancer and gastric cancer.

FDA Approves New Dose Strength of Herceptin Biosimilar for HER2-Overexpressing Breast, Gastric Cancers

FDA fast tracks Sun Pharma and Moebius Medical’s MM-II treatment for osteoarthritis knee pain, with Phase III clinical trials planned to expedite a potential approval.

FDA Grants Fast Track Designation to Non-Opioid Treatment for Osteoarthritis Knee Pain

It’s essential for commercial success, but presents its share of obstacles.

Legal & Regulatory